Medicare’s Unprecedented Alzheimer’s Drug Decision


Medicare’s Unprecedented Alzheimer’s Drug Decision

January 20, 2022

Medicare’s Unprecedented Alzheimer’s Drug Decision

Last week, Medicare took an unprecedented step to restrict patients’ access to the first new Alzheimer’s disease treatment in nearly 20 years. We talk with a doctor, a patient and a former federal official about this unusual move and its wide-ranging implications.


Jay Reinstein, Alzheimer’s disease patient and advocate

Sharon Sha, MD, MS, Clinical Associate Professor of Neurology and Neurological Sciences, Stanford University

Sean Tunis, MD, MSc, Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health, former FDA advisor and former CMS official

Read a full transcript and dig deeper into the issues explored in today’s episode on our website.

Support this type of journalism today by making a donation.

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff.

Follow us on Twitter.

See for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

Proudly supported by:

Treatment for Alzheimer’s Disease: Diet, Exercise and Lifestyle Changes Hear from people living with Alzheimer's about lifestyle changes they’ve adopted to continue leading active, social lives.